Trial Profile

A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1522 in Patients With Advanced Breast Cancer and Other Advanced Tumors Expressing HER2

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs XMT 1522 (Primary)
Indications Adenocarcinoma; Advanced breast cancer; Gastric cancer; HER2 positive breast cancer; Non-small cell lung cancer
Focus Adverse reactions; First in man
Sponsors Mersana Therapeutics

23 Feb 2021 Status changed from active, no longer recruiting to completed.
08 Jan 2019 Status changed from recruiting to active, no longer recruiting.
17 Sep 2018 According to the Mersana Therapeutics media release, protocol amendment of the study includes, increased monitoring as well as the exclusion of patients with advanced hepatic impairment. Also, alternative dosing regimens will be evaluated that is the trial will begin with a once-every-four-week dose regimen. (company may evaluate additional regimens as well).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com